Israel - English - Ministry of Health

trupharm marketing 1985 ltd. - hydrocortisone; lidocaine as hydrochloride - spray - hydrocortisone 0.2 %w/w; lidocaine as hydrochloride 1 %w/w - hydrocortisone - hydrocortisone - for the symptomatic relief of anal and perianal pain and pruritis such as associated with haemorrhoids.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - clotrimazole - solution - clotrimazole 1 % - clotrimazole - clotrimazole - skin infection caused by dermatophytes or candida species.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - clotrimazole - cream - clotrimazole 1 %w/w - clotrimazole - clotrimazole - for the treatment of fungal infections of the skin and mucosa caused be dermatophytes, yeasts, molds and other fungi such as malassezia furfur as well as skin infections caused by corynebacterium minutissimum.indicated also for candida vulvitis and candida balanitis.

Israel - English - Ministry of Health

megapharm ltd - imiquimod - cream - imiquimod 5 % - imiquimod - imiquimod - indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients. for the treatment of actinic keratoses in adults with normal immune systems. for the treatment of superficial basal cell carcinoma in adults with normal immune systems when surgical methods are less appropriate.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.23 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.46 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - capsules - ozanimod as hydrochloride 0.92 mg - ozanimod - zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features.zeposia is indicated for the treatment of moderately to severely active ulcerative colitis (uc) in adults.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - fedratinib as dihydrochloride monohydrate - capsules - fedratinib as dihydrochloride monohydrate 100 mg - fedratinib - inrebic® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (mf)

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - luspatercept - powder for solution for injection - luspatercept 25 mg - luspatercept - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non-transfusion-dependent beta-thalassaemia

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - luspatercept - powder for solution for injection - luspatercept 75 mg - luspatercept - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non-transfusion-dependent beta-thalassaemia